Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment
Category: #health  By Nikita Chaurasia  Date: 2020-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment

According to credible sources, the University of Oxford has announced that it will be initiating the Recovery Trial for testing REGN-COV2, an experimental drug developed for the treatment of the COVID-19 virus.

Sources with relevant information stated that a batch of COVID-19 patients in most of NHS (National Health Service) acute hospitals will be randomly subjected to the testing of the novel drug.

For the record, REGN-COV2 has been developed by U.S.-based Regeneron Pharmaceuticals Inc. by combining two human antibodies that neutralize the mutant viruses. The company had previously developed a similar drug against the Ebola virus.

Unlike the initially developed dexamethasone, the new drug specifically targets the COVID-19 virus and has successfully proceeded to its last stage trials in the U.S.

Peter Horby, Chief investigator of the trial as well as a professor of emerging infectious diseases and global health at the Oxford University, was reported stating that although the university has observed positive outcomes of dexamethasone while treating COVID-19 patients, additional new drugs need to be explored to cope with the soaring death rate.

Martin Landray, a professor of medicine & epidemiology and Deputy Chief investigator of the trial expressed his enthusiasm towards the development and stated that the Recovery trial will enable vigorous assessment of REGN-COV2 among hospitalized patients.

However, experts are skeptical over the affordability of the new antibody vaccine, considering the cost of dexamethasone was around £5 to treat a patient with coronavirus.

In other news, British researchers will reportedly test inhaled COVID-19 vaccines developed by Imperial College and Oxford University. As per reliable sources, the trial is aimed at checking whether direct dosage to the respiratory tract can give a better immune response than conventional dosage methods. 

Source credits: https://www.theguardian.com/world/2020/sep/14/new-antibody-drug-added-to-oxford-university-trial-of-covid-19-treatments

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...